Steve Colletti

Steve Colletti has extensive experience in the biotechnology and pharmaceutical industries. Steve currently holds the role of Chief Scientific Officer at Korro Bio, Inc. since February 2023. Prior to that, they worked at Zymergen as a Senior Vice President from May 2021 to February 2023. Steve was also the Chief Scientific Officer at Lodo Therapeutics Corporation from an unknown date in 2020 to May 2021, and before that, they were the Senior Vice President and Head of R&D at Lodo Therapeutics Corporation from an unknown date in 2018 to March 2020. Earlier in their career, Steve held various roles at Merck, including Executive Director, Head of Therapeutic Modalities from 2013 to 2018, Senior Director, Head of RNA Therapeutics Medicinal Chemistry from 2008 to 2013, Program Leader / Senior Research Fellow, Medicinal Chemistry from 2002 to 2008, and Medicinal Chemist from 1994 to 2002.

Steve Colletti's education history includes a Ph.D. in Chemistry from Boston University, which they obtained between the years 1987 and 1992. Following this, they pursued a NIH Postdoctoral Research Fellowship in Chemistry at Scripps Research between 1992 and 1994.